Charles River Laboratories International Quarterly Cash Flow Statement
NYSE: CRLHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Charles River Laboratories International free cash flow
In the quarter ended Jun 27, 2026, Charles River Laboratories International generated $179.7 million of operating cash flow and spent $31.1 million on capital expenditures. That left free cash flow of $148.6 million, a free-cash-flow margin of 14.8% of revenue. Free cash flow was down 12.2% from the prior year's $169.3 million.
Charles River Laboratories International returned $115.6 million to shareholders through share repurchases, equal to 78% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Charles River Laboratories International cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-27 | Q1 20262026-03-28 | Q4 20252025-12-27 | Q3 20252025-09-27 | Q2 20252025-06-28 | Q1 20252025-03-29 | Q4 20242024-12-28 | Q3 20242024-09-28 | Q2 20242024-06-29 | Q1 20242024-03-30 | Q4 20232023-12-30 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -760.00K | -14.80M | -276.29M | 55.56M | 52.69M | 25.88M | -213.75M | 70.30M | 94.26M | 74.48M | 188.95M | 88.02M |
| Net Income growth (YoY) | -101.44% | -157.20% | — | -20.97% | -44.10% | -65.26% | -213.12% | -20.14% | -5.21% | -28.35% | -0.08% | -9.83% |
| Depreciation & Amortization | 67.29M | 67.15M | 78.28M | 85.16M | 119.51M | 120.36M | 102.10M | 88.20M | 86.08M | 85.36M | 80.51M | 78.87M |
| Stock-Based Compensation | 19.78M | 22.38M | 17.63M | 23.27M | 17.05M | 13.13M | 17.23M | 19.33M | 16.59M | 16.74M | 19.52M | 22.80M |
| Change in Working Capital | -2.86M | -13.66M | -39.56M | -3.85M | 22.30M | -27.20M | 4.11M | 26.04M | 12.80M | -265.00K | 1.83M | -27.03M |
| Operating Cash Flow | 179.72M | 41.08M | 147.52M | 213.83M | 204.60M | 171.70M | 159.36M | 251.79M | 193.53M | 129.89M | 220.94M | 205.45M |
| Capital Expenditures | -31.11M | -55.91M | -88.95M | -35.58M | -35.30M | -59.32M | -75.62M | -38.72M | -39.49M | -79.14M | -78.32M | -65.95M |
| Investing Cash Flow | 28.10M | -407.85M | -92.81M | -33.70M | -37.34M | -45.48M | -76.10M | -21.32M | -61.87M | -85.79M | -238.37M | -79.56M |
| Share Repurchases | -115.60M | -208.28M | -96.00K | -93.00K | -7.35M | -353.13M | -124.00K | -100.79M | -8.91M | -9.35M | -139.00K | -38.00K |
| Debt Issued | 352.80M | 912.46M | 156.67M | 107.50M | 547.02M | 416.34M | 104.80M | 235.58M | 440.32M | 300.88M | 443.32M | 51.24M |
| Debt Repaid | -390.25M | -355.68M | -207.82M | -253.79M | -738.31M | -149.39M | -176.78M | -329.65M | -694.86M | -292.48M | -320.77M | -213.86M |
| Financing Cash Flow | -164.66M | 347.72M | -51.86M | -152.62M | -226.92M | -105.33M | -75.88M | -207.54M | -285.86M | 18.35M | 123.57M | -162.87M |
| Net Change in Cash | 42.38M | -17.80M | 6.78M | 24.48M | -46.99M | 26.16M | -6.07M | 30.64M | -157.53M | 54.05M | 118.86M | -43.16M |
| Free Cash Flow | 148.62M | -14.83M | 58.57M | 178.25M | 169.31M | 112.37M | 83.75M | 213.07M | 154.05M | 50.74M | 142.62M | 139.50M |
This table shows 12 quarterly periods of Charles River Laboratories International's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CRL's reporting calendar. What is a cash flow statement?